Listen: The serious side of spit kits, how BiTEs leave a mark, & Sarepta’s sluggish study
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Dorothy Pomerantz joins us to explain what it’s like to learn devastating medical information from the website of a consumer genetic testing company. Later, Amgen executive Dr. Greg Friberg joins us to explain why the company is betting on BiTEs, an approach to cancer immunotherapy that could succeed where CAR-Ts falter. Then, we dive into why Sarepta Therapeutics is yet to start an important clinical trial it promised the FDA three years ago. Finally, Friberg comes back for a special lightning round, featuring takes on pizza geography, the Four Horsemen of biotech, and whether Los Angeles is misunderstood.
